Public Employees Retirement System of Ohio Raises Position in Medpace Holdings, Inc. $MEDP

Public Employees Retirement System of Ohio increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 12.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 17,968 shares of the company’s stock after purchasing an additional 1,941 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Medpace were worth $8,628,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Geneos Wealth Management Inc. raised its stake in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the period. Steigerwald Gordon & Koch Inc. bought a new position in shares of Medpace during the 4th quarter worth $30,000. Elyxium Wealth LLC bought a new position in shares of Medpace during the 4th quarter worth $30,000. Quarry LP purchased a new stake in Medpace in the 3rd quarter worth about $35,000. Finally, Bayban purchased a new stake in Medpace in the 4th quarter worth about $44,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Robert W. Baird upped their price objective on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday. Royal Bank Of Canada lifted their target price on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research note on Friday. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. TD Cowen upped their price target on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday. Finally, Mizuho raised their price objective on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday. Two equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $560.92.

Medpace Trading Down 2.0%

Medpace stock opened at $589.37 on Tuesday. The firm’s 50 day simple moving average is $495.46 and its 200 day simple moving average is $493.70. The firm has a market capitalization of $16.45 billion, a PE ratio of 34.55, a price-to-earnings-growth ratio of 2.68 and a beta of 1.15. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same period last year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts forecast that Medpace Holdings, Inc. will post 17.59 earnings per share for the current year.

Insider Activity

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 20.50% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.